Recent trials have produced conflicting results on the benefit of epinephrine in patients with OHCA. PARAMEDIC2 was just published and is the largest randomized double-blind, placebo-controlled trial to evaluate the use of epinephrine in OHCA. Dr. Rory Spiegel joins...
Both NIV and HFNC are used to treat patients with acute respiratory failure. Current guidelines recommend NIV for acute respiratory failure caused by COPD...
The use of tranexamic acid (TXA) has markedly increased since the results of the CRASH-II trial were published. In addition to its use in...
Untreated pain, anxiety, and agitation have both short- and long-term consequences for our critically ill patients. More importantly, it is well-known that patients remember...